Andrew John Harvey

This inventor holds 23 USPTO granted patents and 8 published patent applications, plus 3 CIPO patents and 11 EPO patents, primarily in Nicotinic Acetylcholine Receptors. Top assignees: Bionomics Inc., Merck Sharp + Dohme Corp., Cancer Therapeutics Crc Pty Limited. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew John Harvey. Retrieved from https://idiyas.com/inventor/andrew-john-harvey

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 8)

% Patents Active = 60.9

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 11 (Patent Applications = 12)

Average Co-Inventor Count = 6.6

ph-index = 3

Forward Citations = 20(Granted Patents)

Location History:

Thebarton, AU (2016 - 2018)
Goodwood, AU (2012 - 2019)
Paddington, AU (2017 - 2023)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

2 out of 7

Cancer Therapeutics Crc Pty Limited

patents

4. 2 out of 44

Ironwood Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

Areas of Expertise:

Allosteric Modulators

Nicotinic Acetylcholine Receptors

Potassium Channel Blockers

Anxiolytic Compounds

VEGFR3 Inhibitors

Aryl Compounds

Heteroaryl Modulators

Crystalline Forms

Small-Molecules

Bicyclic Compounds

Salts and Co-Crystals

Therapeutics

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12331022 - Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors (2025-06-17),

2. 11793821 - Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors (2023-10-24),

3. 11026958 - Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors (2021-06-08),

4. 10870630 - Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors (2020-12-22),

5. 10266529 - Salts, co-crystals, and polymorphs of an anxiolytic compound (2019-04-23),

6. 9994518 - Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof (2018-06-12),

7. 9926285 - Allosteric modulators of nicotinic acetylcholine receptors (2018-03-27),

8. 9914702 - Amine derivatives as potassium channel blockers (2018-03-13),

9. 9840481 - Allosteric modulators of nicotinic acetylcholine receptors (2017-12-12),

10. 9790173 - Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I (2017-10-17),

11. 9758516 - Crystalline form of an anxiolytic compound (2017-09-12),

12. 9745296 - Salts, co-crystals, and polymorphs of an anxiolytic compound (2017-08-29),

13. 9593096 - α7 nicotinic acetylcholine receptor modulators and uses thereof-III (2017-03-14),

14. 9493451 - Amine derivatives as potassium channel blockers (2016-11-15),

15. 9266864 - VEGFR3 inhibitors (2016-02-23),

Title: The Innovative Contributions of Andrew John Harvey

Introduction

Andrew John Harvey is an esteemed inventor based in Paddington, Australia. With a remarkable portfolio of 10 patents, Harvey has significantly contributed to the field of pharmaceuticals, particularly in developing compounds that target nicotinic acetylcholine receptors.

Latest Patents

Among his latest inventions are two pivotal patents focusing on substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors. These compounds are useful as modulators of α7 nAChR and play a vital role in the treatment and prevention of various central nervous system disorders, including cognitive impairments associated with Alzheimer's disease, Parkinson's disease, and schizophrenia. Furthermore, these innovations also address L-DOPA induced-dyskinesia and inflammation, showcasing the potential for significant advancements in therapeutic approaches.

Career Highlights

Throughout his career, Andrew has worked with prominent companies such as Merck Sharp & Dohme Corporation and Cancer Therapeutics CRC Pty Limited. His experience in these esteemed organizations has allowed him to refine his skills and contribute valuable innovations to the industry.

Collaborations

Harvey has founded notable collaborations with fellow professionals, including Brendan M. Crowley and Ian M. Bell. These partnerships have been instrumental in driving research and development efforts, leading to groundbreaking discoveries in the pharmaceutical field.

Conclusion

Andrew John Harvey’s dedication to innovation and invention has positioned him as a significant contributor to advancements in medicine. His work in developing novel compounds not only underscores his commitment to addressing critical health issues but also highlights the importance of collaboration in driving scientific progress.

Profile summary based on public USPTO records.